Evidence map›Paper›PMID 36812506›Full record

ArticlePLOS digital health2022

Counterfactual analysis of differential comorbidity risk factors in Alzheimer's disease and related dementias.

Yejin Kim, Kai Zhang, Sean I Savitz, Luyao Chen, Paul E Schulz, Xiaoqian Jiang

Open access · goldAbstract read
In one paragraph

Article in PLOS digital health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Genetic variants for Alzheimer's disease and comorbid conditions.Journal of Alzheimer's disease : JAD · 2024
    Article
  3. Article
  4. Inferring Personalized Treatment Effect of Antihypertensives on Alzheimer's Disease Using Deep Learning.Proceedings. IEEE International Conference on Healthcare Informatics · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yejin KimSchool of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.ORCID https://orcid.org/0000-0001-7815-6310
Kai ZhangSchool of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.ORCID https://orcid.org/0000-0002-4519-609X
Sean I SavitzInstitute for Stroke and Cerebrovascular Disease, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.
Luyao ChenSchool of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.ORCID https://orcid.org/0000-0003-4698-5784
Paul E SchulzDepartment of Neurology, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.
Xiaoqian JiangSchool of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.
The University of Texas Health Science Center at Houston · US

Funding

Open Health Natural Language Processing CollaboratoryU01TR002062 · NCATS · MAYO CLINIC ROCHESTER · PI JIANG, XIAOQIAN, LIU, HONGFANG · 2017 to 2021
$7.6M
Finding Combinatorial Drug Repositioning Therapy For Alzheimer'S Disease And Related DementiasR01AG066749 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI JIANG, XIAOQIAN, ZHENG, WENJIN JIM · 2020 to 2024
$4.4M
NCATS NIH HHS U01 TR002062NIA NIH HHS R01 AG066749
6 · The paper itself

Abstract

Alzheimer's disease and related dementias (ADRD) is a multifactorial disease that involves several different etiologic mechanisms with various comorbidities. There is also significant heterogeneity in the prevalence of ADRD across diverse demographics groups. Association studies on such heterogeneous comorbidity risk factors are limited in their ability to determine causation. We aim to compare counterfactual treatment effects of various comorbidity in ADRD in different racial groups (African Americans and Caucasians). We used 138,026 ADRD and 1:1 matched older adults without ADRD from nationwide electronic health records, which extensively cover a large population's long medical history in breadth. We matched African Americans and Caucasians based on age, sex, and high-risk comorbidities (hypertension, diabetes, obesity, vascular disease, heart disease, and head injury) to build two comparable cohorts. We derived a Bayesian network of 100 comorbidities and selected comorbidities with potential causal effect to ADRD. We estimated the average treatment effect (ATE) of the selected comorbidities on ADRD using inverse probability of treatment weighting. Late effects of cerebrovascular disease significantly predisposed older African Americans (ATE = 0.2715) to ADRD, but not in the Caucasian counterparts; depression significantly predisposed older Caucasian counterparts (ATE = 0.1560) to ADRD, but not in the African Americans. Our extensive counterfactual analysis using a nationwide EHR discovered different comorbidities that predispose older African Americans to ADRD compared to Caucasian counterparts. Despite the noisy and incomplete nature of the real-world data, the counterfactual analysis on the comorbidity risk factors can be a valuable tool to support the risk factor exposure studies.

Identifiers

PMID36812506
PMCPMC9931358
OpenAlexW4221094744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.